Patient characteristics of the UD-SCT and chemotherapy groups
| . | UD-SCT No. (%) . | Chemotherapy No. (%) . |
|---|---|---|
| All patients | 81 (100) | 81 (100) |
| Sex | ||
| Male | 56 (69) | 54 (67) |
| Female | 25 (31) | 27 (33) |
| Age at relapse | ||
| Less than 10 y | 50 (62) | 50 (62) |
| 10 y and older | 31 (38) | 31 (38) |
| Immunophenotype | ||
| T cell | 9 (11) | 9 (11) |
| Non-T-cell | 70 (86) | 70 (86) |
| Not specified | 2 (3) | 2 (3) |
| Time of relapse (see text) | ||
| Very early | 22 (27) | 22 (27) |
| Early | 38 (47) | 38 (47) |
| Late | 21 (26) | 21 (26) |
| Site of relapse | ||
| Isolated bone marrow | 63 (78) | 63 (78) |
| Combined | 13 (16) | 13 (16) |
| Isolated extramedullary | 5 (6) | 5 (6) |
| Peripheral blast cell count | ||
| Less than 1/μL | 14 (17) | 14 (17) |
| 1/μL to 10 000/μL | 55 (68) | 55 (68) |
| 10 000/μL and greater | 10 (12) | 10 (12) |
| Unknown | 2 (3) | 2 (3) |
| Risk group (see Table1) | ||
| IR | 28 (35) | 28 (35) |
| HR | 53 (65) | 53 (65) |
| Protocol for relapse therapy | ||
| ALL-REZ BFM 83, 85, 87 | 1 (2) | 9 (17) |
| ALL-REZ BFM 90 | 14 (26) | 35 (66) |
| ALL-REZ BFM 95, 96 | 38 (72) | 9 (17) |
| Conditioning regimen* | ||
| TBI, VP16 and/ or CPM | 50 (70) | NA |
| TBI, Thiotepa, VP16 or CPM | 18 (25) | NA |
| BU, CPM, VP16 or thiotepa | 3 (4) | NA |
| Unknown | 10 (12)† | NA |
| T-cell depletion* | ||
| None | 16 (23) | NA |
| ATG (rabbit/horse) | 52 (73) | NA |
| In vivo depletion, other | 3 (4) | NA |
| Ex vivo depletion | 13 (22) | NA |
| Unknown | 10 (12)† | NA |
| Stem cell source* | ||
| Bone marrow | 56 (78) | NA |
| Peripheral stem cells | 15 (21) | NA |
| Cord blood | 1 (1) | NA |
| Unknown | 9 (11)† | NA |
| HLA mismatch* | ||
| None | 52 (80) | NA |
| 1 antigen class I/II | 4 (7) / 6 (9) | NA |
| 2 antigen class I/II | 3 (5) | NA |
| Unknown | 16 (20)† | NA |
| . | UD-SCT No. (%) . | Chemotherapy No. (%) . |
|---|---|---|
| All patients | 81 (100) | 81 (100) |
| Sex | ||
| Male | 56 (69) | 54 (67) |
| Female | 25 (31) | 27 (33) |
| Age at relapse | ||
| Less than 10 y | 50 (62) | 50 (62) |
| 10 y and older | 31 (38) | 31 (38) |
| Immunophenotype | ||
| T cell | 9 (11) | 9 (11) |
| Non-T-cell | 70 (86) | 70 (86) |
| Not specified | 2 (3) | 2 (3) |
| Time of relapse (see text) | ||
| Very early | 22 (27) | 22 (27) |
| Early | 38 (47) | 38 (47) |
| Late | 21 (26) | 21 (26) |
| Site of relapse | ||
| Isolated bone marrow | 63 (78) | 63 (78) |
| Combined | 13 (16) | 13 (16) |
| Isolated extramedullary | 5 (6) | 5 (6) |
| Peripheral blast cell count | ||
| Less than 1/μL | 14 (17) | 14 (17) |
| 1/μL to 10 000/μL | 55 (68) | 55 (68) |
| 10 000/μL and greater | 10 (12) | 10 (12) |
| Unknown | 2 (3) | 2 (3) |
| Risk group (see Table1) | ||
| IR | 28 (35) | 28 (35) |
| HR | 53 (65) | 53 (65) |
| Protocol for relapse therapy | ||
| ALL-REZ BFM 83, 85, 87 | 1 (2) | 9 (17) |
| ALL-REZ BFM 90 | 14 (26) | 35 (66) |
| ALL-REZ BFM 95, 96 | 38 (72) | 9 (17) |
| Conditioning regimen* | ||
| TBI, VP16 and/ or CPM | 50 (70) | NA |
| TBI, Thiotepa, VP16 or CPM | 18 (25) | NA |
| BU, CPM, VP16 or thiotepa | 3 (4) | NA |
| Unknown | 10 (12)† | NA |
| T-cell depletion* | ||
| None | 16 (23) | NA |
| ATG (rabbit/horse) | 52 (73) | NA |
| In vivo depletion, other | 3 (4) | NA |
| Ex vivo depletion | 13 (22) | NA |
| Unknown | 10 (12)† | NA |
| Stem cell source* | ||
| Bone marrow | 56 (78) | NA |
| Peripheral stem cells | 15 (21) | NA |
| Cord blood | 1 (1) | NA |
| Unknown | 9 (11)† | NA |
| HLA mismatch* | ||
| None | 52 (80) | NA |
| 1 antigen class I/II | 4 (7) / 6 (9) | NA |
| 2 antigen class I/II | 3 (5) | NA |
| Unknown | 16 (20)† | NA |